Products - Liver cancers | Topic | NICE

Showing 12 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC